Quest Diagnostics Attracts Hedge Fund Interest Following Strong Haystack MRD Clinical Data

Quest Diagnostics (NYSE: DGX) has drawn notable attention from hedge funds in recent weeks, following the release of compelling clinical data for its Haystack MRD colorectal cancer test.

Hedge Fund Buying Surges

According to regulatory filings for the period ending September 30, 2026, hedge funds increased their collective Quest Diagnostics shareholdings from approximately 322,000 shares to about 1.44 million shares—a 347% surge. Prominent investors such as Hamlin Capital Management, Confluence Investment Management, and Eastern Bank were among the largest holders driving this shift. This represents a striking uptick in institutional interest toward DGX. 

This development was reported by Holdings Channel, which specializes in tracking hedge fund activity. 

Haystack MRD Clinical Results Boost Confidence

The buying spree coincides with the company’s October 1 announcement detailing robust clinical performance of its Haystack MRD test in a cohort from the landmark DYNAMIC colorectal cancer trials. The test demonstrated 100% specificity at both 3- and 5-year follow-up intervals, with sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence. These figures underscore the test’s potential as a highly reliable tool in colorectal cancer surveillance. 

This data release appears to have played a role in renewed investor confidence, highlighting the promise of advanced diagnostics within Quest’s portfolio.

Stock Performance and Broader Context

As of October 20, 2026, DGX shares traded at $237.12, reflecting a modest 0.47% increase for the day. While trading moves have been limited in the short term, the increase in hedge fund ownership suggests growing institutional optimism consistent with the positive clinical update. 

This uptick comes ahead of Quest Diagnostics’ upcoming third-quarter earnings report, scheduled for release on October 22, 2026. Investors and analysts will now be watching closely for how Haystack MRD contributes to revenues, margins or upcoming guidance. 

Significance and What to Watch Next

The surge in hedge fund holdings may signal anticipation of Haystack MRD serving as a new growth driver, possibly influencing future adoption across clinical settings. However, it’s essential to note that institutional interest—while noteworthy—is not a confirmed indicator of broader market impact or commercial success.

With the third-quarter results imminent, key factors investors will monitor include any commentary on MRD test volume, reimbursement trends, and commercialization roadmap. How competitors respond and Medicare or payer coverage developments, particularly for advanced diagnostics, may also shape DGX’s trajectory.

For now, the dovetailing of strong clinical validation with hedge fund accumulation positions Quest Diagnostics at an important strategic inflection point. The next earnings report could provide further clarity on whether Haystack MRD can evolve from clinical promise to financial momentum.